Intec is moving closer to data from its clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP). The AP is specifically designed to improve gastroretention as a controlled release solution for difficult-to-formulate drugs. The lead programme is a Phase III study of AP-CDLD (carbidopa and levodopa) in Parkinson’s, which is expected to be completely enrolled in Q417. It is also in a Phase I clinical study (targeting Q317 completion) of AP-CDB/THC (cannabidiol and tetrahydrocannabinol) for the treatment of pain and is seeking a development partner for is sleep aid, AP-ZP (zaleplon).

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs